Cwm LLC buys new shares in Verona Pharma plc (NASDAQ:VRNA)

Cwm LLC acquired a new stake in Verona Pharma plc (NASDAQ:VRNA – Free Report) during the second quarter, Holdings Channel reports. The institutional investor acquired 2,000 shares of the company’s stock, valued at approximately $29,000.

A number of other institutional investors have recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. purchased a new stake in Verona Pharma in the fourth quarter valued at $40,000. Jump Financial LLC acquired a new stake in Verona Pharma in the 4th quarter valued at $226,000. Matisse Capital acquired a new stake in shares of Verona Pharma in the 1st quarter worth $312,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Verona Pharma by 35.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 20,200 shares of the company’s stock worth $325,000 after buying an additional 5,322 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Verona Pharma in the 1st quarter worth $373,000. Institutional investors and hedge funds own 85.88% of the company’s shares.

Verona Pharma trading down 3.4%

Shares of VRNA stock opened at $27.05 on Friday. The company’s 50-day moving average price is $20.46 and its 200-day moving average price is $17.14. The company has a current ratio of 8.61, a quick ratio of 8.61, and a debt-to-equity ratio of 0.72. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -35.13 and a beta of 0.44. Verona Pharma plc has a 12-month low of $11.39 and a 12-month high of $28.83.

Verona Pharma (NASDAQ:VRNA – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.53). In the same quarter last year, the business earned ($0.11) EPS. As a group, equities analysts predict that Verona Pharma plc will post -2.07 earnings per share for the current year.

Analyst upgrades and downgrades

A number of equities research analysts recently issued reports on the stock. HC Wainwright upped their target price on shares of Verona Pharma from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Truist Financial boosted their target price on shares of Verona Pharma from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Friday, June 28th. Finally, Canaccord Genuity Group boosted their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Five research analysts have rated the stock with a buy rating. Verona Pharma has a consensus rating of “Buy” and a consensus price target of $36.00, based on data from MarketBeat.

Get the latest report on VRNA

About Verona Pharma

(Free report)

Verona Pharma plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company’s product candidate is ensifenthrine, a dual, inhaled phosphodiesterase (PDE) 3 and PDE4 enzyme inhibitor that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in phase 3 clinical trials for the treatment of the disease. chronic obstructive pulmonary disease, asthma and cystic fibrosis.

Further reading

Want to see what other hedge funds own VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma plc (NASDAQ:VRNA – Free Report).

Get news and reviews for Verona Pharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Verona Pharma and related companies with MarketBeat.com’s FREE daily email newsletter.